CMI Participates in Major Study to Improve Alzheimer’s, Dementia Diagnoses
Category : NEWS
Chesapeake Medical Imaging Participates in Major Study
to Improve Alzheimer’s, Dementia Diagnoses
As a registered amyloid PET imaging site, Chesapeake Medical Imaging recently worked with area specialists to participate in Imaging Dementia—Evidence for Amyloid Scanning (IDEAS), a $100 million study to determine the clinical usefulness of scanning brain amyloid deposits to help evaluate patients with memory loss. In all, CMI completed Medicare-covered amyloid PET (positron emission tomography) scans for 136 patients over the past several months.
“We are thrilled to contribute to this important research, which will provide critical information regarding diagnoses, and treatment of those suffering memory loss,” says Dr. Kevin Berger, a respected imaging expert in Alzheimer’s disease, who has developed quantitative analysis tools for scan interpretation.
With no single test currently available, diagnosing Alzheimer’s is based on patient history, physical examination and cognitive testing. Amyloid PET imaging represents a potential major advance in the assessment of people with cognitive impairment, by visualizing plaques in the brain –prime suspects in damaging and killing nerve cells. Previously, these plaques could only be detected by examining the brain at autopsy.
Nearly 19,000 patients are part of the IDEAS study, which is sponsored by the American College of Radiology (ACR) and American College of Radiology Imaging Network, with funding and direction provided by the Alzheimer’s Association, the ACR and the manufacturers of the FDA-approved radiopharmaceuticals for amyloid imaging.
The CMI team looks forward to monitoring the results of the study as they become available, and participating in future trials to support this effort.
Chesapeake Medical Imaging is Maryland’s premier provider of radiology services, with 14 locations across Anne Arundel County, the Baltimore area, and the Eastern Shore.